DE60041974D1 - 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren - Google Patents

5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren

Info

Publication number
DE60041974D1
DE60041974D1 DE60041974T DE60041974T DE60041974D1 DE 60041974 D1 DE60041974 D1 DE 60041974D1 DE 60041974 T DE60041974 T DE 60041974T DE 60041974 T DE60041974 T DE 60041974T DE 60041974 D1 DE60041974 D1 DE 60041974D1
Authority
DE
Germany
Prior art keywords
treatment
methylindirubine
human solid
solid tumors
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60041974T
Other languages
English (en)
Inventor
Gerhard Prof Dr Eisenbrand
Heinz Herbert Fiebig
Weici Tang
Doris Marko
Ralph Hoessel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60041974D1 publication Critical patent/DE60041974D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
DE60041974T 1999-04-12 2000-04-11 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren Expired - Fee Related DE60041974D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99106206 1999-04-12
EP99107474 1999-04-29
PCT/EP2000/003210 WO2000061124A2 (en) 1999-04-12 2000-04-11 Use off cell membrane penetrating indigoid bisindole derivatives

Publications (1)

Publication Number Publication Date
DE60041974D1 true DE60041974D1 (de) 2009-05-20

Family

ID=26152939

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60041974T Expired - Fee Related DE60041974D1 (de) 1999-04-12 2000-04-11 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren

Country Status (11)

Country Link
US (1) US6664285B1 (de)
EP (1) EP1218004B1 (de)
JP (1) JP2002541189A (de)
CN (1) CN1378447A (de)
AT (1) ATE427746T1 (de)
AU (1) AU775633B2 (de)
BR (1) BR0009771A (de)
CA (1) CA2369626C (de)
DE (1) DE60041974D1 (de)
MX (1) MXPA01010436A (de)
WO (1) WO2000061124A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10125763A1 (de) * 2001-05-17 2002-11-28 Schering Ag Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
DE60237993D1 (de) * 2001-12-13 2010-11-25 Natrogen Therapeutics Inc Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs
EP1340745A1 (de) * 2002-02-20 2003-09-03 Gerhard Prof. Dr. Eisenbrand Indirubinderivate und deren Verwendung zur Behandlung von Krebs
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
FR2952819A1 (fr) * 2009-11-23 2011-05-27 Oreal Composition contenant au moins un precurseur de coloration derive d'oxindole et au moins un colorant indoline dione
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN103333161B (zh) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
CN103274987A (zh) * 2013-06-07 2013-09-04 华东师范大学 3,3-二取代氧化吲哚衍生物及其合成方法和应用
CN103342674B (zh) * 2013-07-05 2015-08-19 华东师范大学 一类光学活性吡咯衍生物及其合成方法
KR101493324B1 (ko) 2013-07-11 2015-02-16 연세대학교 산학협력단 인디루빈 유도체를 포함하는 골길이 성장 촉진용 조성물
CN110305056A (zh) * 2019-05-22 2019-10-08 西北大学 靛玉红新衍生物及其药用用途
CN114533755B (zh) * 2022-03-23 2024-05-03 遵义医科大学 一种绞股蓝多糖与靛玉红在抗黑色素瘤药物上的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS609023B2 (ja) * 1981-06-19 1985-03-07 イスクラ産業株式会社 インジルビン誘導体およびそれを含有する抗腫瘍剤
JPS609022B2 (ja) * 1981-06-19 1985-03-07 イスクラ産業株式会社 インジルビン誘導体およびそれを含有する抗腫瘍剤
JPS617254A (ja) * 1984-06-20 1986-01-13 Isukura Sangyo Kk ビスインドリノンおよびそれを主成分とする制癌剤
US5935581A (en) * 1996-07-24 1999-08-10 Kapadia; Govind J. Inhibitory effects of synthetic and natural colorants on carcinogenesis
ES2194468T3 (es) * 1998-05-29 2003-11-16 Centre Nat Rech Scient Uso de derivados del bisindol indigoide para la fabricacion de un medicamento para inhibir quinasas dependientes de ciclinas.
CN1207924A (zh) * 1998-08-07 1999-02-17 刘克贤 治疗口腔、咽喉、食道疾病的药物及其制备方法
HUP0200724A3 (en) 1999-04-12 2002-10-28 Eisenbrand Gerhard Indigoid bisindole derivatives and pharmaceurical compositions containing them

Also Published As

Publication number Publication date
WO2000061124A2 (en) 2000-10-19
WO2000061124A3 (en) 2002-05-02
US6664285B1 (en) 2003-12-16
JP2002541189A (ja) 2002-12-03
CN1378447A (zh) 2002-11-06
AU4294900A (en) 2000-11-14
EP1218004B1 (de) 2009-04-08
BR0009771A (pt) 2002-01-08
ATE427746T1 (de) 2009-04-15
CA2369626A1 (en) 2000-10-19
AU775633B2 (en) 2004-08-05
CA2369626C (en) 2009-01-13
EP1218004A2 (de) 2002-07-03
MXPA01010436A (es) 2002-09-18

Similar Documents

Publication Publication Date Title
ATE427746T1 (de) 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren
TR200003206T2 (tr) İndol türevleri ve patolojik hücre çoğalmasının neden olduğu habis hastalıklar ve diğer hastalıkların tedavisinde kullanımları.
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE60113733D1 (de) Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
ATE324877T1 (de) Behandlung von metastatischer krankheit
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
DE60045508D1 (de) Dalda-analoge und ihre verwendung
TR199903154T2 (xx) Meme kanserinin tedavisi ve te�hisi i�in bile�imler ve y�ntemler
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
NO20050640L (no) Rutenium anticancer komplekser
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE69713300T2 (de) Benzopyran derivate mit leukotrien-antagonistischer wirkung
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE293991T1 (de) VERWENDUNG EINES MIT DEM PEPTID ßELAGIGILTVß ASSOZIIERTEN ENTEROBAKTERIEN-PROTEINS OMPA ZUR BEHANDLUNG VON MELANOMEN
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE362365T1 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloylderivaten und alkylierungsmitteln

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee